Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $25.00 by Analysts at Royal Bank of Canada
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its target price cut by analysts at Royal Bank of Canada from $26.00 to $25.00 in a report issued on Monday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank of Canada’s target price points to a potential downside of 0.20% from […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its target price cut by analysts at Royal Bank of Canada from $26.00 to $25.00 in a report issued on Monday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank of Canada’s target price points to a potential downside of 0.20% from […]
